CD8A and neoplasm: The combination of axitinib with CTLA-4 inhibitor reduced tumor growth, increased survival and increased the number of CD4+ and CD8+ T cells, intratumoral DCs and suppressive MDSCs in both the intracranial and subcutaneous models [72].